| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0531-5565(00)00178-9 |
| P698 | PubMed publication ID | 11121682 |
| P50 | author | Josef Penninger | Q1674391 |
| P2093 | author name string | Kong YY | |
| P2860 | cites work | Bone cancer gain without the pain | Q73766092 |
| Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord | Q73766127 | ||
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis | Q28141482 | ||
| TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 | ||
| Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival | Q28142897 | ||
| The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor | Q28285539 | ||
| The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily | Q28291317 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice | Q29547898 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Role of cytokines in rheumatoid arthritis | Q29620713 | ||
| Cell biology of the osteoclast | Q33700885 | ||
| Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction | Q33886695 | ||
| Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 | ||
| Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 | ||
| TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation | Q36368029 | ||
| TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells | Q38336153 | ||
| Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 | ||
| RANKing the importance of measles virus in Paget's disease | Q40326890 | ||
| Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells | Q41016675 | ||
| The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. | Q41649459 | ||
| A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. | Q41687961 | ||
| Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. | Q52192178 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| P304 | page(s) | 947-956 | |
| P577 | publication date | 2000-10-01 | |
| P1433 | published in | Experimental Gerontology | Q15766996 |
| P1476 | title | Molecular control of bone remodeling and osteoporosis | |
| P478 | volume | 35 |
| Q34225188 | Basic and clinical aspects of osteoporosis in inflammatory bowel disease. |
| Q35998003 | Bone disorders associated with the human immunodeficiency virus: pathogenesis and management |
| Q42586718 | CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany |
| Q36493469 | Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells |
| Q64891933 | Effects of RANKL, osteoprotegerin, calcium and phosphorus on survival and activation of Muscovy duck osteoclasts in vitro. |
| Q33527233 | Effects of volatile components and ethanolic extract from Eclipta prostrata on proliferation and differentiation of primary osteoblasts. |
| Q35588448 | Enhancement of periodontal tissue regeneration by transplantation of osteoprotegerin-engineered periodontal ligament stem cells |
| Q78052193 | Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells |
| Q38799005 | Estradiol deficiency is a risk factor for idiopathic benign paroxysmal positional vertigo in postmenopausal female patients |
| Q34412527 | Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. |
| Q44731463 | Fourier transform infrared microscopic imaging: effects of estrogen and estrogen deficiency on fracture healing in rat femurs |
| Q39675739 | In vitro: osteoclastic activity studies on surfaces of 3D printed calcium phosphate scaffolds. |
| Q79903139 | Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia |
| Q36565219 | Inflammatory bowel diseases as secondary causes of osteoporosis |
| Q35024511 | Mediators of periodontal osseous destruction and remodeling: principles and implications for diagnosis and therapy |
| Q80160630 | Oral administration activity determination of recombinant osteoprotegerin from silkworm larvae |
| Q35025528 | Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective |
| Q91697796 | Osteoprotective action of low-salt diet requires myeloid cell-derived NFAT5 |
| Q47852837 | Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status |
| Q37694061 | RANK/RANKL/OPG role in distraction osteogenesis |
| Q35084899 | Rheumatic manifestations of human immunodeficiency virus infection |
| Q34333682 | Selective Runx2-II deficiency leads to low-turnover osteopenia in adult mice |
| Q44192941 | Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study |
| Q28576330 | Synergistic effects of green tea polyphenols and alphacalcidol on chronic inflammation-induced bone loss in female rats |
| Q34700421 | The aging of the immune system. |
| Q44113788 | The association between corticosteroid use and development of fractures among IBD patients in a population-based database |
| Q45104630 | The effects of alpha-viniferin on adjuvant-induced arthritis in rats |
| Q35831861 | The prevention of adjuvant hormonal therapy-induced bone loss in women with breast cancer. |
| Q38183343 | The role of osteoclasts in bone tissue engineering |
| Q35373142 | Type I saikosaponins a and d inhibit osteoclastogenesis in bone marrow-derived macrophages and osteolytic activity of metastatic breast cancer cells |
Search more.